Home
Learn More
Search Archives
Business Wire News
Business Wire Services
July 4, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
ViewNews™  
RSS  
 
EON: Enhanced Online News. Powerful technology and tools to help optimize your news content and enhance online visibility for major search engines.
A key component to your social networking and viral marketing strategy. In partnership with industry leader PRWeb.
 
All Press Releases for April 29, 2008 Subscribe to this News Feed      
 

Prostate Cancer Startup CivaTech Oncology Reaches Funding Goal

RESEARCH TRIANGLE PARK, N.C. (Business Wire EON) April 29, 2008 -- CivaTech Oncology, Inc., an early stage company developing a novel medical device for the treatment of prostate cancer, has raised $1,000,000 in a Series B private financing round. The Company was founded in 2006 by Robert and Claudia Black (two of the founders of Sicel Technologies) and Suzanne Babcock (former VP of Troxler Electronics) and is headquartered in the Park Research Center in RTP.

Our approach will allow clinicians to provide a customized radiation source, which will help to ensure optimized patient treatment.
The product focus is on low-dose-rate brachytherapy, a type of radiation treatment for cancer utilizing implanted radioactive sources to kill tumor cells. At present, this type of brachytherapy is used predominantly for prostate cancer and makes use of so-called seeds, which are implanted in a minimally invasive surgical procedure. Civatech Oncologys new device is more akin to a radioactive string that will replace the individual seeds and should provide more uniform and consistent radiation delivery to patients. Brachytherapy has been shown to be as effective as surgery and external beam radiation therapy in studies of long-term patient survival.

The Company is in the final stages of collecting the data needed to submit a 510(k) application to the FDA for its first product. Concurrently, the Company is focusing on fine-tuning the production method. The Company has established strong proprietary protection with an issued U.S. patent and pending applications based on recent work.

The goal of the Company is to provide a better product for the patient and the clinician while at the same time reduce the time and cost of manufacturing. We believe our product will become the gold standard, states Dr. Black, President of CivaTech Oncology. Our approach will allow clinicians to provide a customized radiation source, which will help to ensure optimized patient treatment.

Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/RW1wdC1TdW1tLU1hZ24tU3VtbS1GYWx1LVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web



OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION

CivaTech Oncology Inc.
Claudia A. Black, 919-314-5515
cblack@civatechonology.com
http://www.civatechoncology.com

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files by creating a Smart News Release at Business Wire.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases, please contact the company listed in the press release (see "Contact Information" in the right hand navigation panel). Please do not contact Business Wire or PRWeb®, as we will be unable to assist you with your inquiry.

Business Wire and PRWeb® disclaim responsibility for all content contained in these releases. Our complete disclaimer appears here.
 

About Us   |   Contact Us   |   Privacy Statement   |   Terms of Use (Updated)   |   © Business Wire 2006